▎ 摘　　要

NOVELTY - Conjugate molecule (I) is new. USE - (I) are useful for treating: a hyperproliferative disorder in a patient, where the hyperproliferative disorder is a cancer; glaucoma or of reversing central or peripheral anticholinergia in the patient; confusion or dementia in the patient; a bacterial infection in the patient that has cystic fibrosis, where at least the first beta -lactam antibiotic component is a first monobactam component; and inflammation in the patient which is associated with a disorder consisting of type I diabetes, cancer, Alzheimer's disease, cachexia, muscle-wasting diseases, allergies, rheumatoid arthritis, scleroderma, rheumatic fever, inflammatory bowel disease, myasthenia gravis, multiple sclerosis, Guillain-Barre syndrome, conjunctiva of the eye, systemic lupus erythematosus, encephalitis, adult respiratory distress syndrome, psoriasis, emphysema or muscular dystrophy (all claimed). No biological data given. DETAILED DESCRIPTION - Conjugate molecule (I) having of formula ((CBNC-(L)(cc))m-B1-((L)(a)-A)n) (I-a), ((PCAN-(L)(pc))m-B1-((L)(a)-A)n) (I-b), ((PCAN1-(L)(pc))m-B1-((L)(a)-A)n) (I-c), ((CBN-(L)(c))m-B1) (I-d), ((CBN-(L)(c))-B1a-((L)a-A)) (I-e), ((CBN-(L)(c))-B1-((L)a-A)n2) (I-f), and ((CBN1-(L)(c)1)m1(CBN2-(L)(c)2)m2B-((L)(a)-A)n) (I-g), is new. CBNC = cannabinoid conjugate component comprising a agent component covalently linked, directly or via a linker, to a cannabinoid component; (L)(cc) = CBNC linker, which may be absent; B1 = target binding component which is an antibody; (L)(a) = active component linker; A = active component; m = 1-30; n = 0-29, where the sum of m+n is 1-30, and CBNC is (Ia) a Type I-A cannabinoid conjugate component, where the agent component is directly linked to the cannabinoid component and the agent component is e.g. -Q-NH-C(O)-NH-O-H (Q is e.g. CO and CS), (Ib) a Type I-B cannabinoid conjugate component, in which the agent component is (i) covalently attached to a via a Type I-B linker, where the Type I-B linker is covalently attached to a first hydroxy group of the first cannabinoid component, or a first carboxylic acid group of the first cannabinoid component, or (ii) the agent component is covalently attached to a first hydroxy group or a first carboxylic acid group of the cannabinoid component, and the agent component is e.g. -X (where X is Cl, Br or I), and the Type I-B linker is e.g. -Y1-C(O)- (where Y1 is e.g. 1-12C linear or branched alkyl, optionally substituted with 1-9 F atoms, and/or 1-3 substituents including group one substituents), or (Ic) a Type I-C cannabinoid conjugate component in which the agent component is covalently attached to hydroxy of the cannabinoid component via a cannabinoid component (IC) linker, and the agent component is a beta -lactam antibiotic component, where (1a) the beta -lactam antibiotic component is a cephem component, a carbacephem component, a penem component or a carbapenem component covalently attached at its 3 position to the Type I-C linker, or (1b) the beta -lactam antibiotic component is a monobactam component covalently attached at its 2 position to the Type I-C linker; PCAN = platinum complex anti-neoplastic agent component; (L)(pc) = PCAN linker, which may be absent, where PCAN comprises (1A) a central platinum atom, (2A) a non-leaving ligand component comprising a first non-leaving ligand and a second non-leaving ligand, a first non-leaving ligand, a second non-leaving ligand, and a third non-leaving ligand, a bidentate non-leaving ligand and a tridentate non-leaving ligand, and (3A) a leaving ligand component consisting of e.g. a first leaving ligand and a second leaving ligand, where the first leaving ligand is the first cannabinoid leaving ligand; PCAN1 = platinum complex anti-neoplastic agent component, where PCAN1 comprises e.g. a central platinum atom, and a non-leaving ligand component consisting of a first non-leaving ligand and a second non-leaving ligand, a first non-leaving ligand, a second non-leaving ligand and a third non-leaving ligand, a bidentate non-leaving ligand and a tridentate non-leaving ligand; CBN = cannabinoid component; (L)(c) = cannabinoid component linker, which may be absent; B1a = e.g. cluster of differentiation antigen, checkpoint inhibitor, vascular target antigen, stromal antigen, and extracellular matrix antigen; n2 = 2-29; CBN1 = first cannabinoid component; (L)(c)(1) = first cannabinoid component linker, which may be absent; CBN2 = second cannabinoid component; (L)(c)(2) = second cannabinoid component linker, which may be absent; m1, m2 = 1-30; and n = 0-29, where the sum of m1, m2, and n is 2-30. INDEPENDENT CLAIMS are also included for: (1) a pharmaceutically acceptable salt of the conjugate molecule (I); (2) a composition comprising the conjugate molecule (I) or its salt and a vehicle; (3) treating (M1) a hyperproliferative disorder in a patient, comprising administering the conjugate molecule (I); (4) treating (M2) glaucoma or of reversing central or peripheral anticholinergia in the patient, comprising administering a Type I-A conjugate molecule, where the agent component is a physostigmine-based carbamate component; (5) treating (M3) confusion or dementia in the patient, comprising administering a Type I-A conjugate molecule, where the agent component is a rivastigmine-based carbamate component; and (6) treating (M4) a bacterial infection in the patient, comprising administering a Type I-C conjugate molecule.